Stock Track | MannKind Plunges 6.75% Pre-market as Company Discontinues Key Phase 3 Trial

Stock Track

Nov 10, 2025

MannKind Corporation (MNKD) shares tumbled 6.75% in pre-market trading on Monday following the company's announcement to discontinue its ICON-1 Phase 3 clinical trial. The trial was testing nebulized clofazimine for NTM lung disease, a key pipeline candidate for the biopharmaceutical company.

The decision to halt the trial came after an independent Data Safety Monitoring Board (DSMB) agreed to discontinue the study due to futility. This means that the trial was unlikely to meet its primary efficacy endpoints, dealing a significant blow to MannKind's drug development efforts in this area.

Despite this setback, the company stated that the development of MNKD-102 remains under consideration. However, the discontinuation of the ICON-1 trial represents a major setback for MannKind's pipeline, which likely explains the sharp decline in its stock price. Investors are reassessing the company's growth prospects in light of this development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1197438942"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197438942\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197438942?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197438942","market":"hk","top_or_hot":-1,"title":"Stock Track | MannKind Plunges 6.75% Pre-market as Company Discontinues Key Phase 3 Trial","media":"Stock Track","content":"<p>MannKind Corporation (MNKD) shares tumbled 6.75% in pre-market trading on Monday following the company's announcement to discontinue its ICON-1 Phase 3 clinical trial. The trial was testing nebulized clofazimine for NTM lung disease, a key pipeline candidate for the biopharmaceutical company.</p>\n\n<p>The decision to halt the trial came after an independent Data Safety Monitoring Board (DSMB) agreed to discontinue the study due to futility. This means that the trial was unlikely to meet its primary efficacy endpoints, dealing a significant blow to MannKind's drug development efforts in this area.</p>\n\n<p>Despite this setback, the company stated that the development of MNKD-102 remains under consideration. However, the discontinuation of the ICON-1 trial represents a major setback for MannKind's pipeline, which likely explains the sharp decline in its stock price. Investors are reassessing the company's growth prospects in light of this development.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MannKind Plunges 6.75% Pre-market as Company Discontinues Key Phase 3 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MannKind Plunges 6.75% Pre-market as Company Discontinues Key Phase 3 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-10 21:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MannKind Corporation (MNKD) shares tumbled 6.75% in pre-market trading on Monday following the company's announcement to discontinue its ICON-1 Phase 3 clinical trial. The trial was testing nebulized clofazimine for NTM lung disease, a key pipeline candidate for the biopharmaceutical company.</p>\n\n<p>The decision to halt the trial came after an independent Data Safety Monitoring Board (DSMB) agreed to discontinue the study due to futility. This means that the trial was unlikely to meet its primary efficacy endpoints, dealing a significant blow to MannKind's drug development efforts in this area.</p>\n\n<p>Despite this setback, the company stated that the development of MNKD-102 remains under consideration. However, the discontinuation of the ICON-1 trial represents a major setback for MannKind's pipeline, which likely explains the sharp decline in its stock price. Investors are reassessing the company's growth prospects in light of this development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNKD","symbol_name":"曼恩凯德生物医疗","start_time":0,"source_url":"","article_id":"1197438942","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197438942","pubTimestamp":1762779892,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MannKind Corporation (MNKD) shares tumbled 6.75% in pre-market trading on Monday following the company's announcement to discontinue its ICON-1 Phase 3 clinical trial. The trial was testing nebulized...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNKD":"曼恩凯德生物医疗"},"translate_title":"个股追踪|MannKind盘前暴跌6.75%公司终止关键3期试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1},"content_text":"MannKind Corporation (MNKD) shares tumbled 6.75% in pre-market trading on Monday following the company's announcement to discontinue its ICON-1 Phase 3 clinical trial. The trial was testing nebulized clofazimine for NTM lung disease, a key pipeline candidate for the biopharmaceutical company.\nThe decision to halt the trial came after an independent Data Safety Monitoring Board (DSMB) agreed to discontinue the study due to futility. This means that the trial was unlikely to meet its primary efficacy endpoints, dealing a significant blow to MannKind's drug development efforts in this area.\nDespite this setback, the company stated that the development of MNKD-102 remains under consideration. However, the discontinuation of the ICON-1 trial represents a major setback for MannKind's pipeline, which likely explains the sharp decline in its stock price. Investors are reassessing the company's growth prospects in light of this development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}